FIELD: chemistry.
SUBSTANCE: claimed inventions deal with a modified protein, nucleic acid, coding such protein, a vector, containing nucleic acid, and a carrier for biotin binding, which such protein is immobilised on. The characterised modified biotin-binding protein is obtained by the introduction of a mutation from one to several amino acid residues into a sequence, represented in SEQ ID NO:2, or an amino acid sequence, identical to the said sequence by 98% or more, and the presence of the biotin-binding activity, where at least one residue, selected from the group, consisting of residues from 1) to 4), presented below, is substituted with the residue of acidic amino acid or residue of neutral amino acid; 1) residue of arginine in position 104 SEQ ID NO: 2; 2) residue of lysine in position 141 SEQ ID NO: 2; 3) residue of lysine in position 26 SEQ ID NO: 2 and 4) residue of lysine in position 73 SEQ ID NO: 2.
EFFECT: claimed inventions make it possible to obtain the biotin-binding protein and can be applied for biotin binding.
14 cl, 6 dwg, 11 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
MODIFIED TAMAVIDIN | 2011 |
|
RU2591524C2 |
MODIFIED BIOTIN-BINDING PROTEIN, FUSION PROTEINS BASED THEREON AND THEIR APPLICATION | 2012 |
|
RU2632651C2 |
MUTANTS OF ACTIVATION INDUCED CYTIDINE DEAMINASE (AID) AND METHODS OF APPLYING THEREOF | 2010 |
|
RU2537264C2 |
HEMAGLUTININ MUTANTS OF THE INFLUENZA VIRUS | 2019 |
|
RU2800938C2 |
ANTIBODIES TO BIOTIN AND APPLICATION METHODS | 2013 |
|
RU2630296C2 |
IMMUNOGEN PEPTIDE AGAINST GROUP A STREPTOCOCCI | 2018 |
|
RU2775621C2 |
AAV MUTANT WITH ABILITY TO TARGET BRAIN | 2020 |
|
RU2809389C2 |
MUTANT IMMUNOGLOBULIN-BINDING POLYPEPTIDES | 2015 |
|
RU2701695C2 |
VERSIONS OF DISINTEGRIN AND THEIR PHARMACEUTICAL APPLICATION | 2015 |
|
RU2685869C1 |
LIBRARY OF CONCENTRATION-DEPENDENT ION BINDING MOLECULES | 2012 |
|
RU2812861C1 |
Authors
Dates
2015-05-20—Published
2009-08-13—Filed